Le Lézard
Classified in: Health
Subject: PER

Lotus Clinical Research Announces the Addition of Robert Dworkin, PhD as Director, Chronic Pain Research

PASADENA, Calif., Jan. 15, 2019 /PRNewswire/ -- Lotus Clinical Research, a specialty analgesic full-service CRO, has announced the addition of Robert (Bob) Dworkin, Ph.D. as Director of Chronic Pain Research. In his new role, Dr. Dworkin will lead Lotus' current chronic pain research programs and work to expand Lotus' chronic pain expertise and capabilities.

Lotus Clinical Research

"Lotus Clinical Research is the leading CRO for acute pain analgesic clinical trials. I am very enthusiastic to be collaborating with their strong, experienced, analgesic CRO team as they grow their chronic pain base and increase the number of chronic pain clinical trials," said Dworkin. "I strongly endorse the Lotus mission to develop and validate innovative methods to improve the scientific accuracy of analgesic clinical trials and thereby accelerate the development of treatments with improved efficacy and safety. These efforts have great potential to reduce prescription drug abuse and help combat the opioid crisis, and I appreciate their focus on designing and conducting scientifically rigorous analgesic trials."

Robert H. Dworkin, Ph.D., received his BA from the University of Pennsylvania and his Ph.D. from Harvard University and has served as a consultant to over 160 pharmaceutical and device companies in the development and evaluation of analgesic and antiviral treatments. He has been the principal investigator for a large number of clinical trials funded by government and industry, which have examined treatments for various types of chronic pain, including painful diabetic peripheral neuropathy, low back pain, osteoarthritis, cancer pain, fibromyalgia, and postherpetic neuralgia, as well as treatments for acute post-surgical pain and shingles pain.

Dr. Dworkin has spent over 35 years conducting clinical research on acute and chronic pain. In addition to his position at Lotus, he is currently Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, Professor in the Center for Health + Technology, and Director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry; Director of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration (FDA); Special Government Employee of the FDA Center for Drug Evaluation and Research; and Associate Editor of Pain and a member of the Editorial Boards of Canadian Journal of Pain and Journal of Pain.

The primary focus of Dr. Dworkin's current research involves the identification of factors that increase the assay sensitivity of clinical trials to detect differences between an active and a placebo control or comparison treatment. In ongoing studies, he and his colleagues are examining the relationships between clinical trial results and their research designs, patient characteristics, statistical methods, and outcome measures. Dr. Dworkin has also been very interested in the identification of risk factors for the transition from acute to chronic pain. In joining Lotus Clinical Research, Dr. Dworkin is responsible for leading chronic pain development efforts and assisting with further building our CRO infrastructure to further expand our resources and drive anticipated growth. 

"Lotus Clinical Research is steadily expanding its capabilities and scope by building a world-class analgesic leadership team, committed to meeting our clients' and society's needs," said Lotus CEO, Neil Singla, MD. "With Dr. Dworkin and other key leaders in place, we're well equipped to deliver truly comprehensive analgesic clinical trial services in both acute and chronic pain."

"Dr. Dworkin is perhaps the world's leading expert in chronic pain clinical trials, and as the driving force behind the ACTTION public-private partnership, he has significantly advanced the field of analgesic research globally," said Dr. Singla. "Dr. Dworkin and I have collaborated for many years in research supported by ACTTION and in advising shared pharmaceutical clients on their pain programs. His new position with Lotus adds significant depth to our scientific team and bolsters Lotus' ability to lead the CRO space in chronic pain study design and conduct."

About Lotus Clinical Research: Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments and has played a role in 10 analgesic FDA approvals. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain providing scientific leadership at every step of the development process. In assisting with the advancement of pain therapies, Lotus Clinical Research seeks to invent and operationalize research methods that improve study design and conduct for analgesic trials, which support our mission to help alleviate the opioid crisis in society. 

Hadley Rakowski
Lotus Clinical Research

Related Images


Related Links

Lotus Clinical Research website

Lotus Clinical Research LinkedIn

SOURCE Lotus Clinical Research

These press releases may also interest you

at 02:17
January 1 ? December 31, 2018 The fourth quarter in figures Net sales amounted to TSEK 2,030 (1,886).The loss after tax amounted to TSEK 11,506 (10,295). The loss per share amounted to SEK 0.69 (1.13). The cash flow from current operations was...

at 02:16
Period October ? December 2018  Revenues amounted to SEK 0.6 (0.0) million Operating result amounted to SEK ?22.5 (?22.6) million Result after tax amounted to SEK ?22.5 (?22.4) million, corresponding to SEK ?0.33 per share (?0.36) before and after...

at 01:58
"We summarize 2018 and conclude: RaySearch stands strong. Order intake rose by 19 percent and RayCare has been introduced into clinical use"  Johan Löf, CEO of RaySearch. Comments page 3.  YEAR IN BRIEF For full-year 2018, order intake increased 19...

at 01:52
Sosei Group Corporation ("the Company"; TSE: 4565), announces that the first healthy subject has been dosed with a novel small molecule HTL0030310 in a Phase I clinical study, marking the start of a new in-house clinical program targeting endocrine...

at 01:00
Mothers' Milk Bank of North Texas (MMBNT) has moved into a new 13,090 square foot facility, marking the beginning of a new chapter for the nonprofit. The building in southwest Fort Worth features three times the space of the former location enabling...

at 00:49
ROKIT Healthcare, Inc., a regenerative medicine company focused on the development of novel regenerative therapeutic strategies using three-dimensional (3D) biofabrication technologies for treatment of various medical conditions including...

News published on 15 january 2019 at 17:38 and distributed by: